Gastroenterology | Phase I Developments

Applied Molecular Transport

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Inflammatory Disease Biotech Applied Molecular Transport Files for a $100 Million IPO

Lead Product(s): AMT-101

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: BofA Securities

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 18, 2020

Details:

The IPO will bankroll both Phase II trials for AMT-101 that they plan to begin this year, and a Phase I trial for AMT-126, an IL-22 agonist being developed for diseases that are related to barrier function.

Aerpio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease Product Candidate GB004

Lead Product(s): GB004

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Gossamer Bio

Deal Size: $105.0 million Upfront Cash: $15.0 million

Deal Type: Licensing Agreement May 12, 2020

Details:

The renegotiated licensing deal is intended to place Gossamer Bio in a better position to progress GB004, and in addition, is designed to facilitate the further development of each company’s respective pipelines.

Assembly Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Preclinical Data from Assembly Biosciences’ Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal

Lead Product(s): ABI-M201

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

Assembly’s lead live biotherapeutic product candidate, ABI-M201, is being evaluated in a Phase 1b trial in patients with mildly to moderately active UC and ongoing treatment with mesalamine.

Innovation Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis

Lead Product(s): Brilacidin

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

Details:

The Company is presently interviewing Contract Research Organizations for site selection with the understanding that the goal is to initiate the trial this summer.

Anokion SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease

Lead Product(s): KAN-101

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

First-in-human study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten-free diet (GFD).

PvP Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Takeda buys PvP in $330M deal to bag a 2nd celiac drug

Lead Product(s): TAK-062

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: $330.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition February 26, 2020

Details:

The acquisition was triggered following the conclusion of a Phase 1 proof- of-mechanism study of investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac disease.

Pandion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101

Lead Product(s): PT101

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2020

Details:

Trial to evaluate safety and tolerability of PT101, as well as expansion of regulatory T cells.

Gossamer Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation

Lead Product(s): GB004

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

The presentation showcased GB004 program at the 15th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO).

Innovation Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints

Lead Product(s): Brilacidin

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

Preliminary top-line data from its Phase 1 trial (NCT03234465) studying the use of delayed-release tablets of Brilacidin showed the trial met its primary endpoints.

Emmaus Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial

Lead Product(s): Glutamine

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

A marginal but decreased size in some of the diverticula compared to the baseline. Indications of Healing and Normalization of Bowel Movements Observed in the Initial Patient.

Find

Find Gastroenterology Drugs in Phase I Clinical Development

Phase I

A collaboration with SCORR Marketing

Product Type

Companies

Applied Molecular Transport

Inflammatory Disease Biotech Applied Molecular Transport Files for a $100 Million IPO

Aerpio Pharmaceuticals

Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease Product Candidate GB004

Assembly Biosciences

Preclinical Data from Assembly Biosciences’ Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal

Innovation Pharmaceuticals

Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis

Anokion SA

Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease

PvP Biologics

Takeda buys PvP in $330M deal to bag a 2nd celiac drug

Pandion Therapeutics

Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101

Gossamer Bio

Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation

Innovation Pharmaceuticals

Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints

Emmaus Life Sciences

Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial